

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 103029

Title: Phase angle as a prognostic biomarker in metastatic colorectal cancer - a

prospective trial

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 08349585 Position: Peer Reviewer Academic degree: PhD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Croatia

Manuscript submission date: 2024-11-05

Reviewer chosen by: Shang Wu

Reviewer accepted review: 2024-12-04 04:30

Reviewer performed review: 2024-12-12 08:56

Review time: 8 Days and 4 Hours

	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair
this manuscript	[] Grade D: No creativity or innovation



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y] Yes [] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

I have carefully reviewed the manuscript titled "Phase angle as a prognostic biomarker in metastatic colorectal cancer - a prospective trial." The study addresses an important clinical question regarding the use of phase angle (PA) as a prognostic marker in patients with metastatic colorectal cancer (mCRC) undergoing first-line chemotherapy. The manuscript is generally well-structured, and the research appears to be methodologically sound. 1. The study provides valuable insights into the role of PA as an objective pre-chemotherapy prognostic factor in mCRC. The findings that a high PA (≥4.60°) is associated with longer median progression-free survival are novel and could have significant implications for patient stratification and treatment planning. 2.The prospective observational design strengthens the validity of the findings. However, the single-institution design may limit the generalizability of the results. It would be beneficial if the authors could discuss this limitation and its potential impact on the findings. 3. The use of ROC curve analysis to determine the PA cut-off value is appropriate. Nevertheless, the manuscript would be strengthened by additional sensitivity analyses to evaluate the robustness of this cut-off value. 4. The results indicate



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: office@baishideng.com

https://www.wjgnet.com

a significant difference in PFS between the high and low PA groups, but no difference in objective response rate (ORR). The authors should discuss potential reasons for this discrepancy and its clinical implications. 5. The discussion is comprehensive, but it could be enhanced by comparing the findings with other studies that have used different methodologies or populations. Additionally, the authors might consider discussing the potential mechanisms underlying the association between PA and survival outcomes. 6. Figure 2: The Kaplan-Meier curves are informative, but the number of patients at risk for each time point should be included in the figure or the figure caption for better clarity. 7. No specific details on the randomization process and allocation concealment were provided in the manuscript. This is a very important part of prospective trials to ensure the reliability of the results and reduce bias. 8. The manuscript utilized the Kaplan-Meier and Log-Rank tests, which are standard methods in survival analysis. However, the article did not mention whether corrections were made for possible confounding factors, such as age, gender, tumor stage, etc. In conclusion, the manuscript presents important findings that contribute to the field of oncology. With some revisions, particularly in addressing the generalizability and providing additional analyses, the study could be a valuable addition to the literature.